- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Tocilizumab improved survival in patients hospitalized with severe COVID-19: Lancet
UK: Treatment with tocilizumab improved survival and other clinical outcomes in COVID-19 patients hospitalized with hypoxia and systemic inflammation, show findings from RECOVERY trial published in The Lancet. The benefits were evident irrespective of the amount of respiratory support and were in addition to the benefits of systemic corticosteroids.
RECOVERY Collaborative Group aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation.
Randomised Evaluation of COVID-19 Therapy (RECOVERY) -- a randomised, controlled, open-label, platform trial assessed several possible treatments in patients hospitalised with COVID-19 in the UK. It included people with hypoxia (oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein ≥75 mg/L). They were randomly assigned in the ratio of 1:1 to receive usual standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 mg-800 mg (depending on weight) given intravenously. A second dose could be given 12-24 h later if the patient's condition had not improved.
The primary outcome was 28-day mortality, assessed in the intention-to-treat population.
A total of 4116 patients were included in the assessment of tocilizumab, including 3385 (82%) patients receiving systemic corticosteroids, between April 23, 2020, and Jan 24, 2021.
Key findings of the study include:
- 31% of the 2022 patients allocated tocilizumab and 35% of the 2094 patients allocated to usual care died within 28 days (rate ratio 0·85).
- Consistent results were seen in all prespecified subgroups of patients, including those receiving systemic corticosteroids.
- Patients allocated to tocilizumab were more likely to be discharged from hospital within 28 days (57% vs 50%).
- Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (35% vs 42%).
"Our findings show that treatment with tocilizumab in patients hospitalised with severe COVID-19 reduced mortality, increased the chances of successful hospital discharge, and reduced the chances of requiring invasive mechanical ventilation. These benefits are additional to those previously reported for dexamethasone," wrote the authors.
"These findings require an update to clinical guidelines, which has already begun, and efforts to increase the global availability and affordability of tocilizumab," they concluded.
Reference:
The study titled, "Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial," is published in The Lancet.
DOI: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00676-0/fulltext
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751